Library
AB-FUBINACA is a synthetic cannabinoid of the indazolecarboxamide class. Originally developed by Pfizer in 2009 as an analgesic, it was never pursued for human use and first surfaced in synthetic cannabinoid blends in Japan in 2012. It is a highly potent cannabinoid receptor agonist, and its extreme potency (combined with its widespread inclusion in unregulated herbal blends) poses significant overdose risk, with fatalities reported.
Also known as: Ab-fub, Ab-fubi
Dosage
Duration
No data available for this section yet.
Dosage
Duration
No data available for this section yet.
Dosage
Duration
No data available for this section yet.
Dosage
Duration
Check interactions before mixing substances, pay attention to dose spacing and hydration, and treat all dosage guidance as approximate rather than guaranteed safe.
Substance data is aggregated from the following public harm-reduction and reference sources.
This static page is intended as a readable non-JS and prerender-friendly library export.
Open the interactive DrugsPRO app for search, saved items, interactions, and deeper harm reduction tools.
Get the PRO test kit. The simple, quick and reliable drug checking test kit. Visit https://protestkit.eu
